Products
CD274 antibody
Cited Publications
(6)
Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy IF: 4.4
EJNMMI Radiopharmacy and Chemistry · 2025-02-07
Deoxynivalenol upregulates hypoxia-inducible factor-1α to promote an “immune evasion” process by activating STAT3 signaling IF: 3.9
Food and Chemical Toxicology · 2024-07-12
Tc-Labeled Cyclic Peptide Targeting PD-L1 as a Novel Nuclear Imaging Probe IF: 5.4
Pharmaceutics · 2023-12-01
Synthesis and Evaluation of 177Lu-DOTA-PD-L1-i and 225Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy IF: 5.6
International Journal of Molecular Sciences · 2023-08-11
PD-L1 expression is linked to tumor-infiltrating T cell exhaustion and adverse pathological behavior in pheochromocytoma/paraganglioma IF: 5
Laboratory Investigation · 2023-07-07
ScRNA-seq revealed an immunosuppression state and tumor microenvironment heterogeneity related to lymph node metastasis in prostate cancer IF: 8.593
Experimental Hematology & Oncology · 2023-06-02
Product Inquiry
FNab06280 — CD274 antibody